On Tuesday, Gilead Sciences, Inc. released a statement declaring that the Food and Drug Administration (FDA) has approved a methodological refinement for the manufacturing of Yescarta, a therapy produced by its subsidiary Kite Pharma. This modification will decrease the median turnaround time for the therapy in the United States from 16 days to just 14 days.
The median turnaround time refers to the period it takes from leukapheresis—the process of extracting a patient's T cells—to the point when the therapy is ready for use. After the patient's T cells are gathered via leukapheresis, they are transported to Kite's specialized manufacturing plants. Here, they are genetically altered with a Chimeric Antigen Receptor. After individual treatment preparation, the cells undergo comprehensive assessments, preservation procedures, and packaging. Following these steps, they are then shipped back to the hospital for reintroduction into the patient.
Maintaining continuity in the manufacturing process, from leukapheresis to product delivery, is of vital importance due to the critical nature of its timing and scheduling. High precision and punctuality ensure a smooth and uninterrupted supply chain for this therapy.
